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Case Report
Necrotizing myopathy as a paraneoplastic
syndrome associated with renal cell
carcinoma
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1Department of Medical Oncology, 2Department of Neurology, 3Department of Urology, Ghent University
Hospital, Ghent, Belgium
We report a 49-year-old patient with necrotizing myopathy and a right renal mass. After laparoscopic
radical nephrectomy, a remission of myopathy was seen. Pathologic evaluation of the nephrectomy
specimen revealed a clear cell renal cell carcinoma. Relapse of myopathy 6 months postoperatively
coincided with the diagnosis of the appearance of liver metastatic disease. After initiation of treatment with
an mTOR-inhibitor, myopathy became less active requiring smaller amounts of corticosteroids with a
complete remission of myopathy after 3 months of systemic treatment for metastatic renal cell cancer.
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Patient History
A 49-year-old man without significant medical
history presented in June 2010 to the emergency unit
with a 4-month history of muscle pain and weakness,
mainly involving the proximal muscles, accompanied
by subfebrility. Over the last weeks, he had developed
malaise with fatigue, loss of appetite, increased
dyspnea and weight loss of 3 kg.
At the time of hospital admission, his blood
pressure was 120/80 mmHg, heart rate 76 beats per
minute and body temperature 36uC. Notable findings
on physical examination included painful thighs with
muscle weakness grade 4/5 using Medical Research
Council scale.
Laboratory data showed normocytic anemia,
leukocytosis with left shift, thrombocytosis, hypoal-
buminemia, elevated transaminases, markedly ele-
vated serum creatine kinase (1821 U/l, reference
values 10–195 U/l) and lactate dehydrogenase levels
(1439 U/l, reference values 321–462 U/l). Results of
renal function testing and urinalysis were normal.
Viral cytology for Epstein-Barr virus, cytomegalo-
virus, HIV, hepatitis A, B and C was negative.
Ultrasound of the abdomen revealed a 4.667.5 cm
heterogeneous mass in the upper/mid portion of
the right kidney without signs of hydronephrosis.
Further exploration with contrast-enhanced com-
puted tomography (CT) of the abdomen and thorax
confirmed a low-attenuated septated mass in the right
kidney accompanied by enlarged lymph nodes in
the mediastinum and both hili of the lungs (largest
measured 3.9 on 2.3 cm). The patient was transferred
to the urology department to undergo a retroper-
itoneal laparoscopic right radical nephrectomy with
intact specimen extraction. As there were no enlarged
abdominal lymph nodes, lymphadenectomy was not
performed (cN0). A biopsy of the right vastus me-
dialis was performed because of clinical evidence of
myositis.
Pathologic examination revealed a 5-cm renal cell
carcinoma (RCC), clear cell type, Fuhrman grade 2
with negative surgical margins (pT1b).
In a second intervention, mediastinoscopy was
performed for biopsy of one of the subcarinal lymph
nodes. Pathologic examination revealed no malignant
involvement (pN0).
Muscle biopsy revealed a diffuse fiber atrophy with
signs of a mild necrotizing myopathy without
significant inflammation (Fig. 1). At that time,
electromyography was not performed. After admin-
istration of corticosteroids and abundant fluid
administration, his muscle weakness improved and
CK values decreased (Fig. 2). Corticosteroids were
phased out over 6 months because of gastric incon-
venience and maintained on 4 mg alternate day.
During follow-up, the patient showed a new
episode of muscle pain and weakness located at
thighs and shoulders. Laboratory findings again
showed a highly elevated serum creatine kinase
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(10 778 U/l). Electromyography of the upper extre-
mities revealed a myopathic process in the proximal
muscles. A relapse of necrotizing myopathy was
suggested and high dose steroid treatment (64 mg
methylprednisolone) was restarted. A bone scan
could not confirm bone involvement. Investigation
with CT scan revealed a liver metastastic lesion in
combination with bilateral enlarged lymph nodes at
lung hili and mediastinum. After multidisciplinary
discussion, the patient was diagnosed with metastatic
renal cell carcinoma. Weekly administration of the
mTOR (mammalian target of rapamycin) inhibitor
temsirolimus was started (negative prognostic factors
were elevated LDH, anemia, and time from initial
diagnosis to the start of systemic treatment ,1 year)
together with high dose steroids. Two months after
start of administration, the metastatic lesion at the
liver was in remission and serum creatine kinase
normalized. There were no longer signs of muscle
pain or weakness. Given the fact that both temsir-
olimus and steroids have an immunesuppressive
effect, we tried to phase out the steroids as soon as
possible (in about 8 months). Thirty-four months
later, the patient is still receiving temsirolimus and
CT scans demonstrate remaining remission of
the disease according to RECIST criteria, without
clinical signs of myositis and normal CK levels.
Comment
Our patient presented with clinical and serological
abnormalities suggesting a myopathic process, patho-
logically classified as a necrotizing myopathy. There
Figure 2 Evolution of serum creatine kinase during disease course
Figure 1 (A) Muscle biopsy showing a necrotic (large arrow) and a regenerating (small black arrow) muscle fiber indicating a
mild necrotizing myopathy (modified trichrome stain,6400). (B) Immunofluorescence staining shows major histocompatibility
class-I (MHCI) reactivity on the sarcolemma of all muscle fibers (6400)
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was no medication, alcohol or substance abuse
involved and there was no statin exposure. There
were no anamnestic or clinical signs of systemic
rheumatic diseases. Autoimmune serology (anti-CCP,
ANCA, ANF, anti-mitochondrial antibody, anti-Sm,
anti-Ro/SSA) was negative.
Necrotizing autoimmune myopathy (NAM) is a
subtype of idiopathic inflammatory myopathies, a
group of acquired, heterogeneous systemic diseases
that mainly affect the skeletal muscles. The other
three subgroups of idiopathic inflammatory myopa-
thies are dermatomyositis, polymyositis and sporadic
inclusion body myositis. In 2003 Anthony Amato on
behalf of the muscle study group proposed the first
formal definition of NAM: onset over 18 years,
subacute or insidious onset of symmetric proximal
more than distal limb and neck flexor more than neck
extensor weakness, elevated serum CK levels and e.g.
detection of myositis-specific antibodies (MSAs).1
This means a lot of non-specific myositis may have
been falsely classified as dermatomyositis or poly-
myositis in the past. NAM is clinically resembling
polymyositis, but histologically distinct by showing
necrotic muscle fibres with minimal or absent
inflammatory cell infiltration besides macrophages
invading necrotic muscle fibers.2,3
Case reports and small series of patients reveal a
subset of 16% of NAM characterized by anti-signal
recognition particle (anti-SRP) antibodies. Although
it seems to be an MSA, the link between these
antibodies and myositis is not clear yet. Striking is the
presence of additional symptoms like dysphagia or
cardiac involvement and a higher CK level in SRP-
associated myopathy.3,4
Recent data showed a typical association of the anti-
3-hydroxy-3-methylglutaryl-coenzymeA reductase (anti-
HMGCR) antibody and NAM in statin-exposed
patients. However, some patients with dermatomyositis,
polymyositis and sporadic inclusion body myositis
showed these antibodies too and on the other hand
there were anti-HMGCR-positive patients that were not
previously exposed to statins.3,4
Furthermore, NAM can occur in association with
connective tissue diseases (anti-synthetase antibo-
dies). About one-third of NAM is not accompanied
by autoantibodies but may be associated with other
autoimmune diseases or cancer. Neither anti-SRP
nor anti-HMGCR antibodies were linked to cancer.
Because of small series of patients reliable prevalence
data for the four subgroups are not yet available.
Neither SRP testing nor HMGCR testing was
performed in our patient because commercial testing
of the autoantibodies is however not yet available in
Belgium.3,4
As we detected a renal cell carcinoma, the
pathologically proven necrotizing myopathy is very
likely to be a cancer-associated myositis (CAM).
NAM associated with cancer is minute giving the fact
that a rapid positive evolution after short courses of
steroids is seen. However, NAM associated with anti-
HMGCR and anti-SRP antibodies is known for
mostly being slowly reactive to high dose steroids and
to relapse frequently after tapering or stopping of
steroids.4
Approximately 20% of patients diagnosed with
renal cell carcinoma present with a concomitant
paraneoplastic syndrome. Another 10 to 40% of
patients develop paraneoplastic symptoms during the
disease.5
Large epidemiologic studies confirmed the associa-
tion of inflammatory myopathy with cancer. The
strongest association is reported for dermatomyositis
with standardized incidence ratios (SIRs) of 3.8–7.7.
Large studies do show a greater risk of developing
cancer for patients with polymyositis compared with
cancer incidence rate in the general population (SIRs
1.7–2.0). Moreover, studies report that most cancers
develop within two years of the onset of myositis,
although the risk remains increased to 5 years after
diagnosis.6
Dermatomyositis is strongly associated with ovar-
ian, lung, gastric, colorectal and pancreatic cancers.
In patients with polymyositis there was an increased
risk of non-Hodgkin lymphoma, lung and bladder
cancers.3,6,7 The association between cancer and
NAM has been reported, but to a much lesser extent
compared with dermatomyositis and polymyositis.
NAM affects merely adults over the age of 40,
frequently with adenocarcinoma.8 SIR calculation
has not yet been done due to the paucity of cases.2,3,6
No epidemiological data on the relation between
CAM and renal cell carcinoma are available.
Screening for underlying malignancy in patients
with newly diagnosed inflammatory myopathy is
mandatory although there is no consensus on how
extensive screening for associated cancer should
be.3,6,7
The exact pathomechanism of NAM and CAM
remains elusive. There is evidence that the presence
of malignancy and immune-mediated destruction of
muscle or skin is strongly linked in a way that tumor
cells and injured and regenerating muscle cells seem to
possess potential antigenic similarities. The tumor may
thus be an antigen source in myositis and immune
response also targets the injured and regenerating
muscle cells that express the autoantigens.7,9
This positive correlation between tumor immunity
and autoimmunity needs to be further explored.
There seems to be a correlation between the clinical
course of myositis and malignancy, as successful
treatment of the neoplasm will mostly impact on the
muscle symptoms. Importantly, serum CK levels do
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not always correlate with the severity of weakness
and secondly the severity of necrotizing myopathy
does not always parallel tumor progression.3,7,8,10
Approximately 40 to 50% of patients with idiopathic
autoimmune myopathy present MSA. The role of these
MSA such as anti-Jo-1, anti-Mi-2, anti-SRP, anti-MJ
and anti-p155, and myositis-associated-autoantibodies
(MAA, present in autoimmune diseases with or without
myositis) such as anti-PM-Scl, anti-Ku, anti-U1-RNP
and anti-U3-RNP, in patients with myositis to
predict CAM is currently a hot topic. In patients with
paraneoplastic NAM these MSA and MAA can be
either absent, non-specific of only weakly elevated.3,6,7
CAM has a worse prognosis compared to non-
CAM with statistically significant higher mortality
rates in the CAM group. Moreover, death in CAM
almost always results from progression of malignant
disease and not myositis, even in cases where the
myositis is poorly controlled.7,10
In addition, the timely recognition of myositis
onset is therapeutically important and contributes to
morbidity and mortality: in patients where cancer
and dermatomyositis are simultaneously diagnosed,
the disease course is more severe than for those where
the tumor is diagnosed prior to the myositis. It is still
unclear whether or not we can extrapolate these data
to the NAM subgroup.3,7,8
No studies are available that investigate morbidity
and mortality in renal cell cancer versus renal cell
cancer with CAM.
Based on case reports, we know that treatment of
the tumor (surgery, chemotherapy, radiotherapy) may
lead to remission of the myositis. Nevertheless most
patients need extra immunosuppressive therapy (intra-
venous immunoglobulins, azathioprine, methotrexate,
plasmapheresis, etc.) to control myositis and prevent
relapses even if cancer remission is obtained.2,3,7
Conclusion
Paraneoplastic NAM is a rare syndrome. Diagnosis
usually requires amuscle biopsy with typical aberrations.
Treatment with steroids and/or immunotherapy is
suggested beside treatment of underlying neoplasm.
Although disappearance of CAM has already been
reported after surgery, radiotherapy or chemotherapy,
we believe this is the first reported case of NAM
resolving with an mTOR inhibitor in combination with
steroids in a metastatic renal cell cancer patient. Further
investigation is however needed to reveal the exact
pathomechanism of NAM and thus to determine the
exact role of on the one hand steroids and on the other
hand mTOR inhibition in this case.
mTOR inhibition is currently investigated in other
autoimmune disorders like rheumatoid arthritis, multi-
ple sclerosis and hematological diseases. Specific data
about treatment of NAMare however not yet available.
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